# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dos...
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantib...
Wedbush analyst Robert Driscoll reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and maintains $11 price t...
VAV1 is a key signaling protein downstream of both the T-and B-cell receptors and its degradation has potential to treat multip...
The company announced the pricing of an underwritten public offering of 10.638 million shares of its common stock at a public o...
Monte Rosa Therapeutics, Inc. ("Monte Rosa") (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel mol...